Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for FOREX trading professionals · Sunday, June 16, 2019 · 488,180,624 Articles · 3+ Million Readers

Outcome of Annual General Meeting of May 22, 2019

Marseille, France, May 23, 2019, 7:00 AM CEST

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 22, 2019, in Marseille, France. All resolutions were voted in accordance with the management team’s recommendations.

A total of 27,276,527 votes was cast out of a total of 64,039,842 shares with voting rights, representing a quorum of 42.593%.

Details of the votes are available on the Company’s website, in the Annual General Meeting 2019 section.

***
The 2018 Reference Document of the Company is available on its website.

***

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Pioneer in the biology of NK cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com

/EIN News/ --

Information about Innate Pharma shares:

ISIN code

Ticker code

LEI
FR0010331421

IPH

9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

 

Innate Pharma 

Dr. Markus Metzger/ Danielle Spangler
Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

 
International Media

 

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

InnatePharma@consilium-comms.com
  French Media

 

ATCG Press

Solène Moulin / Marie Puvieux

Tel.: +33 (0)9 81 87 46 72

 innate-pharma@atcg-partners.com

 

Attachment

logo.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release